A Phase 2 interventional study of 1.5 mg RPL554 plus tiotropium and 6 mg RPL554 plus tiotropium in Chronic Obstructive Pulmonary Disease Moderate, sponsored by Verona Pharma plc. Completed. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-02-27.
Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 2 under way, 1 of them phase 3. ensifentrine · Pulmonary Disease, Chronic Obstructive.
Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, this one is the 13th largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 2, and was the 3rd registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States
Ages 40–80
By country, each count listing its studies:
ensifentrine: first FDA approval 2024 (OHTUVAYRE). What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 79 across the 15 interventional studies. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 4 most frequent:
This study is registered under Verona Pharma plc, one of the names counted as Merck & Co., Inc. Under that name alone:
Verona Pharma plc is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 15 (65%) have results posted.
Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc, this one is the 22nd largest by enrollment, is one of 2 that started in 2017, is one of 18 in phase 2, and was the 12th registered.
Merck & Co., Inc’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2002.
1 of the studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05270525Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAEffect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Among Merck & Co., Inc’s 26 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
This is a phase II, randomised, double blind, placebo controlled, complete block, three way crossover study to investigate treatment with nebulised RPL554 and tiotropium together in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The purpose of this study is to assess the bronchodilator effect (opening of the airways) of RPL554 when used in combination with a long acting anti-muscarinic receptor antagonist (tiotropium) whilst dosing the RPL554 to steady state blood levels. It is planned to randomise up to 30 patients to have 24 evaluable patients at one study centre. In each treatment period, patients will receive an open label dose of tiotropium from a dry power inhaler (DPI) followed immediately by a double blind dose of either RPL554 6mg, 1.5mg or placebo (depending on treatment sequence) from a nebuliser in the morning on Day 1, Day 2 and Day 3. The dose of RPL554 or placebo will be repeated in the evening on Day 1 and Day 2; there will not be an evening dose on Day 3.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If male: must agree to meet the following from the first dose up to 1 month after the last dose of study treatment:
If female: either be:
Of non-childbearing potential defined as being:
Have a 12-lead recording at screening and randomisation (pre-dose in Treatment Period 1) showing the following:
Have a screening Holter report with a minimum of 18 hours recording that is able to be evaluated for rhythm analysis which shows no abnormality which indicates a significant impairment of patient safety or which may significantly impairs interpretation in the opinion of the Investigator including:
Post-bronchodilator (four puffs of salbutamol) spirometry at screening:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1.5 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
Drug: 1.5 mg RPL554 plus tiotropium
6 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
Drug: 6 mg RPL554 plus tiotropium
Nebulised RPL554 matched placebo twice daily plus 10 mcg tiotropium DPI once daily for 3 days
Drug: Placebo plus tiotropium
Drug pages: Ensifentrine · Tiotropium
Drug pages: Ensifentrine · Tiotropium
Peak Forced Expired Volume in 1 Second (FEV1) on the Third Day of Dosing
Peak forced expired volume in 1 second (FEV1) over 4 hours on the third day of dosing
Time frame: Day 3
Average FEV1 Over 12 Hours on the Third Day of Dosing
Average FEV1 area under the curve (AUC) over 12 hours on the third day of dosing
Time frame: Day 3
Peak FEV1 on Day 1
Peak FEV1 over 4 hours on Day 1
Time frame: Day 1
Average FEV1 Over 12 Hours on Day 1
Average FEV1 AUC over 12 hours on Day 1
Time frame: Day 1
| Milestone | Placebo Then Low Dose RPL554 Then High Dose RPL554 | Low Dose Dose RPL554 Then High Dose RPL554 Then Placebo | High Dose RPL554 Then Placebo Then Low Dose RPL554 | High Dose RPL554 Then Low Dose RPL554 Then Placebo | Low Dose RPL554 Then Placebo Then High Dose RPL554 | Placebo Then High Dose RPL554 Then Low Dose RPL554 |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 6 | 4 | 6 | 4 |
| Completed | 4 | 4 | 6 | 4 | 5 | 3 |
| Not completed | 1 | 1 | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 |
Peak forced expired volume in 1 second (FEV1) over 4 hours on the third day of dosing
| Liters | Lower Dose Nebulised Treatment | Higher Dose Nebulised Treatment | Placebo |
|---|---|---|---|
| Peak Forced Expired Volume in 1 Second (FEV1) on the Third Day of Dosing | 0.477 ± 0.1673 | 0.500 ± 0.2157 | 0.373 ± 0.1970 |
Average FEV1 area under the curve (AUC) over 12 hours on the third day of dosing
| Liters*hour | Lower Dose Nebulised Treatment | Higher Dose Nebulised Treatment | Placebo |
|---|---|---|---|
| Average FEV1 Over 12 Hours on the Third Day of Dosing | 3.804 ± 1.8512 | 3.967 ± 2.2134 | 3.197 ± 2.2826 |
Peak FEV1 over 4 hours on Day 1
| Liters | Lower Dose Nebulised Treatment | Higher Dose Nebulised Treatment | Placebo |
|---|---|---|---|
| Peak FEV1 on Day 1 | 0.383 ± 0.1448 | 0.432 ± 0.1720 | 0.337 ± 0.1854 |
Average FEV1 AUC over 12 hours on Day 1
| Liters*hour | Lower Dose Nebulised Treatment | Higher Dose Nebulised Treatment | Placebo |
|---|---|---|---|
| Average FEV1 Over 12 Hours on Day 1 | 3.058 ± 1.4851 | 3.094 ± 1.9624 | 2.510 ± 1.9381 |
Collected over From informed consent until the end of the study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lower Dose Nebulised Treatment | 0/29 (0%) | 1/29 (3.4%) | 12/29 (41.4%) |
| Higher Dose Nebulised Treatment | 0/27 (0%) | 0/27 (0%) | 12/27 (44.4%) |
| Placebo | 0/28 (0%) | 0/28 (0%) | 12/28 (42.9%) |
| Event | Lower Dose Nebulised Treatment | Higher Dose Nebulised Treatment | Placebo |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/29 | 0/27 | 0/28 |
| Event | Lower Dose Nebulised Treatment | Higher Dose Nebulised Treatment | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 2/29 | 5/27 | 3/28 |
| Medical device site reactionGeneral disorders | 4/29 | 1/27 | 4/28 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/29 | 1/27 | 2/28 |
| Chest discomfortGeneral disorders | 1/29 | 1/27 | 2/28 |
| Catheter site bruiseGeneral disorders | 0/29 | 1/27 | 0/28 |
| ChillsGeneral disorders | 0/29 | 1/27 | 0/28 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/29 | 1/27 | 0/28 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 0/29 | 1/27 | 0/28 |
| Skin infectionInfections and infestations | 0/29 | 1/27 | 0/28 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/29 | 1/27 | 0/28 |
All patients who received at least one dose of study treatment
| Age, Continuous(years) | Overall |
|---|---|
| Median | 64.5 (47 to 73) |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 13 |
| Male | 17 |
| Race (NIH/OMB)(Participants) | Overall |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 30 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Percentage of predicted FEV1 post-bronchodilator(%) | Overall |
|---|---|
| Mean | 60.1 ± 9.73 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Jan 2017, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2019, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ensifentrine · Tiotropium
Pulmonary Disease, Chronic Obstructive →